Editorial

• March/April 2015: Volume 16 Number 3/4

Conference reports

• 2015 Conference on Retroviruses and Opportunistic Infections (CROI), 23-26 February 2015, Seattle

• Pre-CROI meetings and workshops

• CROI webcasts online

• Pipeline ART: tenofovir alafenamide (TAF)

• Pipeline ART: maturation inhibitors and an attachment inhibitor

• No HIV transmissions between gay couples when viral load is undetectable: preliminary results from “Opposites Attract” study in Australia, Thailand and Brazil

• PrEP reduced HIV risk by at least 86% in PROUD: no transmissions likely from people taking meds

• Q&A on the PROUD study and PrEP results from CROI

• “On demand” PrEP dosing in IPERGAY: 86% reduced risk of HIV, no transmissions with active drug use

• Other HIV PrEP studies at CROI 2015: implementation of oral PrEP and problems with tenofovir gel

• Early HIV treatment and isoniazid prophylaxis: why TEMPRANO results do not yet support universal ART at CD4 counts >500

• Unintended pregnancies with levonorgestrel implant due to drug interactions with efavirenz-based ART

• Three drug ART best for preventing vertical transmission to infants: results from the PROMISE study

• 3 in 5 breastfeeding women with viral load >1,000 copies/mL are undiagnosed in Kenya, Malawi and South Africa

• Point of care HIV PCR test for infant diagnosis: good performance but poorer results in youngest age group

• Weekend-off ART is non-inferior to continuous ART in young people taking efavirenz-based regimens: results from BREATHER study

• Increased cardiovascular risks in HIV positive children in Uganda and Zambia partially reversed by ART

• Lopinavir/ritonavir superior to nevirapine in children <3 years old: IMPAACT P1060 five year results

• Long-term safety and efficacy of tenofovir in children

• UK case of HIV remission: ten years off-ART in patient with prior progression and treated during seroconversion

• XXIV International HIV Drug Resistance Workshop
, 21-22 February 2015, Seattle, Washington

• Prevalence of transmitted drug resistance globally: highest in Australia, US and some European countries but between-country differences in all regions

• Higher rates of K65R in non-B subtype in large UK cohort and implications of tenofovir resistance in resource-limited settings

• Drug resistance and integrase inhibitors: potential impact of HIV subtype

• Drug resistance in children after PMTCT and early treatment

Antiretrovirals

• FDA approves fixed dose darunavir/cobicistat

• FDA approves fixed dose atazanavir/cobicistat

• FDA approves fixed dose raltegravir/3TC formulation: Merck holds back from marketing in US

Opportunistic infections and complications

• Recommendations for management of bone disease in HIV

• FDA approves 9-valent HPV vaccine: active against types 6, 11, 16, 18, 31, 33, 45, 52 and 58

Other news

• NHS further delays access to sofosbuvir

• Public Health England outline plans to promote the health and wellbeing of gay and bisexual men

On the web

• START study video

• Diabetes in people with HIV: special issue of RITA

• NAT report: Young MSM in the UK

• Guidance on reporting results of clinical trials

PDFs

• March/April 2015: Volume 16 Number 3/4